10 Under-the-Radar Stocks with Massive Upside for 2026

Page 4 of 4

6. Alumis Inc. (NASDAQ:ALMS)

With an analyst consensus upside of 79.4%, Alumis Inc. (NASDAQ:ALMS) ranks among the under-the-radar stocks with massive upside for 2026.

Alumis Inc. (NASDAQ:ALMS) drew three analyst price target raises after reporting Q1 results and advancing its envudeucitinib pipeline toward a pair of major readouts.

On May 19, 2026, Chardan raised its price target to $40 from $38 and kept a “Buy” rating, citing updated pricing assumptions for envudeucitinib, modest changes in psoriasis penetration estimates, and updated financials after Q1 results. On May 15, 2026, Wells Fargo raised its target to $51 from $49 and kept an “Overweight” rating, arguing the Street-implied probability of success for envudeucitinib’s Phase 2b in systemic lupus erythematosus is too low, creating a favorable risk/reward setup ahead of the Q3 readout. Also on May 15, 2026, Guggenheim analyst Yatin Suneja raised the firm’s target on Alumis Inc. (NASDAQ:ALMS) to $34 from $32 and kept a “Buy” rating, with the higher target reflecting the updated cash position following Q1 results.

Those updates followed Alumis Inc. (NASDAQ:ALMS)’s Q1 2026 report on May 14, 2026.

Alumis Inc. (NASDAQ:ALMS) ended the quarter with $569.5 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the fourth quarter of 2027. Net loss narrowed to $93.1 million from $99.0 million a year earlier. R&D expenses fell to $81.5 million from $96.6 million, primarily due to lower clinical trial costs following completion of enrollment for the pivotal ONWARD1 and ONWARD2 trials.

On the pipeline side, Phase 3 envudeucitinib data presented at the 2026 American Academy of Dermatology meeting showed PASI 90 responses of 68.0% and 62.1%, and PASI 100 responses of 41.0% and 39.5% by Week 24.

Alumis Inc. (NASDAQ:ALMS) remains on track for an NDA submission in Q4 2026 and a potentially pivotal Phase 2b SLE topline readout in Q3 2026.

While we acknowledge the potential of ALMS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ALMS and that has 100x upside potential, check out our report about the cheapest AI stock.

Click to continue reading and see the 5 under-the-radar stocks with massive upside for 2026.

Disclosure: None. Follow Insider Monkey on Google News.

Page 4 of 4
1281292 - 11759070 - 1